Opinion/decision on a Paediatric investigation plan (PIP): Cosentyx, Secukinumab, decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Immunology-Rheumatology-Transplantation, PIP number: P/0282/2023

List of industry subject matter experts and list of planned calls for industry subject matter experts

Herbal medicinal product: Ginseng radixArray, F: Assessment finalised

Herbal medicinal product: Pelargonii radixArray,Array, F: Assessment finalised

Public webinar on pack size submissions: from XEVMPD to product management service (PMS), Online, European Medicines Agency, Amsterdam, the Netherlands, from 11 July 2024, 10:00 (CEST) to 11 July 2024, 11:30 (CEST)

Exploring GLP-1 Receptor Agonists: Instagram LIVE Q&A, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 22 July 2024, 18:00 (CEST) to 22 July 2024, 18:30 (CEST)

EMEA-002886-PIP01-20-M03

EMEA-002819-PIP01-20-M01

EMEA-002631-PIP01-19-M02

Opinion/decision on a Paediatric investigation plan (PIP): Vyvgart, Efgartigimod alfa, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Haematology-Hemostaseology, PIP number: P/0252/2023